Drug intelligence / Profile preview

AR-6121

Development stage: Preclinical
Lead developer: Alcon
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Ophthalmic

Overview

AR-6121 is a small molecule drug candidate developed by Aerie Pharmaceuticals. It is a ROCK (Rho-associated kinase) inhibitor-linked steroid, designed to leverage both the anti-fibrotic and intraocular pressure (IOP)-lowering activities of ROCK inhibitors while generating potent steroidal effects. The primary indication under investigation for AR-6121 is post-procedural inflammation, particularly in ophthalmology settings such as after eye surgery. As of the latest updates, AR-6121 remains in preclinical development with no reported clinical trial results or regulatory approvals[1][2][3][5][9].

Targets

ROCK1 (Rho-associated coiled-coil containing protein kinase 1)

Beyond the preview

Go deeper on AR-6121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR-6121.

Explore the full profile